CJC-1295
Also known as: CJC-1295 with DAC, DAC:GRF, Mod GRF 1-29 (no-DAC form)
Quick summary
CJC-1295 is a modified analogue of growth-hormone-releasing hormone. Research focus: GHRH receptor pharmacology, GH and IGF-1 pharmacokinetics and long-acting peptide design. This page leads with SRP's low-and-slow starting dose.
Amino acid sequence (one-letter code): YADAIFTQSYRKVLAQLSARKLLQDIMSR
Overview
CJC-1295 is a modified analogue of growth-hormone-releasing hormone. The DAC version carries a reactive group that binds serum albumin, stretching its half-life to several days. The no-DAC version (modified GRF 1-29) is short-acting.
Looking for research material? Simple Research Peptides lists CJC-1295 With DAC 10mg for laboratory research use.
Mechanism
A GHRH(1-29) analog. The DAC version has a reactive group that binds albumin in the blood, extending its half-life to several days. The no-DAC version (Mod GRF 1-29) is short-acting. Both stimulate the pituitary GHRH receptor.
Research areas
- GHRH receptor pharmacology
- GH and IGF-1 pharmacokinetics
- long-acting peptide design
Storage & reconstitution
Supplied as a lyophilized powder; keep sealed, dry and away from light, ideally frozen or refrigerated for long-term holding. Laboratories typically reconstitute with bacteriostatic or sterile water, swirling gently rather than shaking, then hold the solution refrigerated (2–8 °C) and use it within the window set by their own stability protocol.
Recommended starting dose (low and slow)
| Starting dose | DAC form: opens at 500-1,000 mcg once weekly; low end 300 mcg. No-DAC form: example opens at 100 mcg once daily; 100-200 mcg 1-3 times daily. |
|---|---|
| Frequency | Reported for the DAC form at about 1-2 mg per week, and the no-DAC form at 100-300 mcg per administration, 1-3 times daily, both subcutaneous. Do not use the DAC schedule with the no-DAC form. |
| Reconstitution | Examples: 2 mg vial + 2 mL bacteriostatic water = 1 mg/mL; 5 mg vial + 2 mL water = 2.5 mg/mL; 5mg vial + 2mL diluent (as listed). storage note: Reconstituted: refrigerate, used within 4 weeks. |
Studied higher doses
Studies have used doses up to the amounts below. Higher doses can be dangerous. Whether a person can reach them safely depends on height, weight, activity level, training and pre-existing conditions. We recommend following the lower starting dose above, and contacting SRP with any questions.
| Highest amount reported in studies | DAC form: 2 mg per week in (1,000 mcg, 1 mg reference). a phase 2 trial used up to 240 mcg/kg/week, far above typical ranges. No-DAC form: 200-250 mcg per administration. |
|---|---|
| Step-up schedules reported | DAC form : 500-1,000 mcg weekly for weeks 1-2, 1,000 mcg weekly for weeks 3-8, optionally 2,000 mcg weekly or 1 mg twice weekly. No-DAC form (example): 100 mcg daily weeks 1-2, 150 mcg weeks 3-4, 200 mcg weeks 5-8. |
Route and timing
Route: Subcutaneous injection after reconstitution is the route most often described in research protocols.
Timing: Pending - to be added by SRP
Cycle length and repeat
Pending - to be added by SRP
Half-life
Approximate, for Bobby's review: With DAC: about 6 to 8 days. Without DAC: about 30 minutes.
Side effects
Pending - to be added by SRP
Suggested bloodwork and monitoring
Draft, for Bobby's review: CBC and comprehensive metabolic panel (kidney and liver function, electrolytes) before starting and again after a few weeks; IGF-1, fasting glucose and HbA1c.
Cautions
Pending - to be added by SRP
Reconstitution calculator
Math aid only. It converts the numbers you enter; it is not dosing advice. For research use only. Prefilled with this page's vial size, reconstitution and low-and-slow starting dose where known; change any value.
Frequently asked questions
What is CJC-1295 studied for?
In research it is studied for GHRH receptor pharmacology, GH and IGF-1 pharmacokinetics and long-acting peptide design. A GHRH(1-29) analog.
How is CJC-1295 given in research?
Subcutaneous injection after reconstitution is the route most often described in research protocols. See the dosing frequency block on this page for how often.
What amount should a researcher start with?
This page lists SRP's low-and-slow starting dose in the Recommended starting dose section. Higher amounts that appear in studies are listed separately with their safety context. Start with the lower dose and contact SRP with any questions.
Related peptides
Last updated: October 19, 2026